Discovering HDL-elevating drugs: are there simplistic approaches to a polygenic disorder?

Area of Science:

• Cardiovascular Research
• Pharmacology
• Biochemistry

Background:

• High-density lipoproteins (HDL) are recognized for their protective role against atherosclerosis.
• Significant efforts have focused on developing HDL-elevating drugs, but progress has been limited compared to LDL-lowering therapies.
• A gap exists in clinically approved HDL-raising medications.

Purpose of the Study:

• To review current strategies for identifying and developing compounds that elevate HDL levels.
• To discuss insights gained from preclinical animal models regarding HDL-elevation mechanisms.
• To outline a hypothesis for testing potential HDL-elevating drugs and explore future research avenues.

Main Methods:

• Review of existing data on HDL-elevating compounds in animal models.
• Analysis of cellular and molecular mechanisms of action for HDL elevators.
• Discussion of proposed strategies for drug discovery and testing.
• Exploration of the role of omics technologies in future research.

Main Results:

• Preclinical studies in animal models have yielded valuable mechanistic insights into HDL elevation.
• Understanding cellular and molecular effects is crucial for targeted drug development.
• A framework for hypothesis-driven testing of HDL-elevating drug candidates is proposed.

Conclusions:

• Targeted strategies informed by preclinical data are essential for advancing HDL-elevating drug development.
• Future research incorporating genomics, transcriptomics, and proteomics holds promise for novel HDL therapies.
• Overcoming current challenges requires a deeper understanding of HDL metabolism and function.